Business Services News

Business Services News

Breaking News on Business Services

Home > Business Services Search Engine                                 

Business Services News -- Video Feeds
  • Advertising
  • Careers
  • Corporate news
  • Economy
  • Markets
  • Small Business
  • Personal Finance
  • Regulatory and Compliance
  • Business News

    Muscarinic Acetylcholine Receptor Market Size Forecast to Reach $1.89 Billion by 2026
    (I-BusinessNews.Com, August 25, 2021 ) Muscarinic Acetylcholine Receptor Market size is forecast to reach $1.89 billion by 2026, growing at a CAGR of 4.1% during the forecast period 2021-2026. Muscarinic Acetylcholine Receptor are kind of receptors that are involved in regulating the number of peripheral and central functions and are able to inhibit postsynaptic neurons. They are responsible for mediating the effects basically the physiological effects of the nerve activity that are parasympathetic. It has both inhibitory as well as excitatory effects that can block or stimulate the response and is stored in the acetylcholine producing neurons as cholinergic neurons. It is an ester of acetic acid and choline that functions to transmit nerve impulses within the peripheral and central nervous systems. Increasing prevalence of disease such as chronic obstructive pulmonary disease and increasing importance of muscarinic acetylcholine disease therapeutics are the major factors driving the growth of the market. Growth in research in muscarinic acetylcholine and rise in the adoption of muscarinic acetylcholine receptor is set to further enhance the overall market development of the Muscarinic Acetylcholine Receptor Market for the period 2021-2026.



    Muscarinic Acetylcholine Receptor Market Segment Analysis – By Product



    Tropicamide held the largest share in the Muscarinic Acetylcholine Receptor Market in 2020 and is estimated to grow at a CAGR of 4.4% during the forecast period 2021-2026. Tropicamide is a muscarinic antagonist having similar actions to atropine with an anticholinergic property. It binds the muscarinic receptors in the ciliary muscle in the eye and in the sphincter. It inhibits the responses from stimulation and produces the dilation of the pupil along with the paralysis of the ciliary muscle. Tropicamide is a diagnostic agent that is used to produce short duration cycloplegia and mydriasis. Owing to the short duration of the effect, it is used during dilated fundus examination. Cycloplegic drops are used to treat uveitis that decreases the risk of synechiae and decreases the inflammation in the anterior chamber of the eye. Tropicamide are estimated to register the higher CAGR over the period 2021-2026.



    Request for Sample Report @ https://www.industryarc.com/pdfdownload.php?id=507041

    Report Price: $ 5900 (Single User License)



    Muscarinic Acetylcholine Receptor Market Segment Analysis – By Application



    Chronic Obstructive Pulmonary Disease held the largest share in the Muscarinic Acetylcholine Receptor Market in 2020 and is estimated to grow at a CAGR of 4.3% during the forecast period 2021-2026. Muscarinic acetylcholine receptor controls smooth muscle tone, inflammation, and mucus secretion in healthy lungs. Cholinergic mechanisms contribute to increase mucus secretion and bronochoconstriction in chronic obstructive pulmonary disease. Muscarinic acetylcholine is not a neurotransmitter but it transcends the parasympathetic nervous system that can modify the phenotypic function of airway cells including the epithelial cells. Chronic Obstructive Pulmonary Disease are estimated to register the higher CAGR over the period 2021-2026.



    Muscarinic Acetylcholine Receptor Market Segment Analysis – By Geography



    North America dominated the Muscarinic Acetylcholine Receptor Market with a major share of 41.8% in 2020. This is attributed to the increasing number of key players that are focusing on developing mAChR for the treatment of Alzeheimers’s disease and increasing number of pharmaceutical companies that are working on new therapies for neurological conditions. Increasing incidences of chronic obstructive pulmonary disease and increased research activity for therapeutic contribution of these receptors are also increasing the growth of the market in this region.



    However, Asia Pacific is estimated to grow at a higher CAGR during the forecast period 2021-2026 owing to the increase in healthcare expenditure and rise in the demand for new treatment for Alzeheimer’s disease.



    Inquiry Before Buying @ https://www.industryarc.com/reports/request-quote?id=507041



    Muscarinic Acetylcholine Receptor Market Drivers



    Increasing Prevalence of Chronic Obstructive Pulmonary Disease



    Increasing prevalence of chronic obstructive pulmonary disease is increasing the growth of the Muscarinic Acetylcholine Receptor Market. Chronic obstructive pulmonary disease causes obstructed airflow from the lungs which includes difficulty in breathing, mucus, and cough. It is mainly caused by long term exposure to particulate matter and irritating gases. People suffering from this have high risk of developing heart disease, and variety of other conditions. Two most common conditions that contribute to it are Emphysema and chronic bronchitis which usually occurs together. It affects 2 to 8% of the population. Thus, increasing the growth of the Muscarinic Acetylcholine Receptor Market during the forecast period 2021-2026.



    Rising Awareness About Muscarinic Acetylcholine Receptor



    Rising awareness about muscarinic acetylcholine receptor is increasing the growth of the Muscarinic Acetylcholine Receptor Market. Neurotransmitter acetylcholine recognized by muscarinic receptors that translates into electrical transients and altered cell behavior by suppressing the signaling pathways. Awareness is rising among the people that it decreases the heart rate and helps in bronchial construction. It makes to breath in asthmatics and enhances the urination by relaxing and contracting the bladder.Thus, increasing the growth of the Muscarinic Acetylcholine Receptor Market during the forecast period 2021-2026.



    Muscarinic Acetylcholine Receptor Market Challenges



    Inadequate funding and high cost involved in the treatment of the diseases



    Some of the factors that are set to impede the growth of the Muscarinic Acetylcholine Receptor Market are inadequate funding and high cost involved in the treatment of the disease. Strict approval process is also set to hinder the growth of the market.



    Muscarinic Acetylcholine Receptor Market Landscape



    Product launches, mergers and acquisitions, joint ventures, and R&D activities are key strategies adopted by players in the Muscarinic Acetylcholine Receptor Market. In 2020, the Muscarinic Acetylcholine Receptor Market share is consolidated by the top ten players present in the market. The Muscarinic Acetylcholine Receptor Market, top 10 companies are Heptares Therapeutics Ltd., Astrazeneca Plc, Karuna Pharmaceuticals Inc., Anavex Life Sciences Corp., NeuroHealing Pharmaceuticals Inc. and Sumitomo Dainippon Pharma Co. Ltd. among others.



    Key Takeaways



    North America dominated the Muscarinic Acetylcholine Receptor Market in 2020 owing to the increasing number of key players who are continuously focusing on developing M1 mAchR agonists for treating Alzheimer’s disease and increasing number of pharmaceutical companies that are working on new therapies for rare neurological conditions. The Muscarinic Acetylcholine Receptor Market scope for different regions will be provided in the final report.



    Growing public awareness and technological advancements along with rising awareness about muscarinic acetylcholine & its prevention are likely to aid the market growth of the Muscarinic Acetylcholine Receptor Market report.



    Detailed analysis of the Strength, Weakness, and Opportunities of the prominent players operating in the market will be provided in the Muscarinic Acetylcholine Receptor Market report.



    Inadequate funding and high cost involved in the treatment of the diseases is poised to create the hurdles for the Muscarinic Acetylcholine Receptor Market.



    Related Reports :



    A. Proteinuria Treatment Market

    https://www.industryarc.com/Report/16208/proteinuria-treatment-market.html



    B. Hydroxytryptamine Receptor Market

    https://www.industryarc.com/Research/Hydroxytryptamine-Receptor-Market-Research-502818



    For more Lifesciences and Healthcare Market reports, please click here



    About IndustryARC: IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications market research. Our Custom Research Services are designed to provide insights on the constant flux in the global supply-demand gap of markets. Our strong team of analysts enables us to meet the client research needs at a rapid speed, with a variety of options for your business. Any other custom requirements can be discussed with our team, drop an e-mail to sales@industryarc.com to discuss more about our consulting services.

    IndustryARC

    Venkat Reddy

    (+1) 970-236-3677

    venkat@industryarc.com

    Source: EmailWire.Com

    Source: EmailWire.com

    Business News Feeds
  • Business News - Top Stories
  • Company Earnings
  • Economy
  • Personal Finance
  • Real Estate
  • Stock Markets
  • Business Services Sponsors

    Business Services Ads

    Business Resource Center
    We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Industry resource center today to browse our selection of 600+ complimentary Industry magazines, white papers, webinars, podcasts, and more. Get popular titles including:

    CIO Insight
    Managed Healthcare Executive
    Mortgage Technology

    No credit cards, coupons, or promo codes required. Try it today!

    Press release service

    :: Home: :: Submit Press Release :: Subscribe to News :: Contact Us :: Help

    For unlimited press release distribution for $59 per month, call (281) 645-4086 or start posting your press releases online at EmailWire.com.

    Copyright 2008 GroupWeb Media LLC
    GroupWeb Media Network

    Aviation-NewsWire | ArtNewsWire | Auction NewsWire | CRM NewsWire | ePhotoNewsWire | Energy Industry | EstateNewsWire | Entertainment-NewsWire.com | Food Beverage News | Glamour NewsWire | Health NewsWire | Hosting NewsWire | i-Auto NewsWire | i-Business News | i-Homeland Security.Com | iMac-NewsWire.Com | i-Press-Release-Service | i-SoftwareNews.com | iT-NewsWire.Com
    | i-TravelNewsWire.Com | MoneyNewsWire.Net | Movie-Stars-News.Com | MSNewsWire.Net | PharmaNewsWire.Com | Publishing-NewsWire.Com | RSSNewsWire.Net | Telecom-NewsWire.Net | Transportation-News.Com | USGovernment-News.Com | WebPosters.Net | Wireless-NewsWire.Com | VoIPNewsWire.Net | XSportsWorld.Net
    I-BusinessNews.Com is a business news service of GroupWeb Media LLC